GlassScriptPhysician profile
John A Anson
NPI 1891752176
$18,406.40
in general payments reported to CMS, 2019-2025
21 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,674 · 2020: $162 · 2021: $296 · 2022: $10K · 2023: $3,108 · 2024: $1,354 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $2,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $2,906.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineology INC. | $8,531.69 | 2022 | |
| Orthofix Medical, INC. | $3,000.00 | 2023 | Manta Ray |
| Providence Medical Technology, INC. | $2,645.13 | 2022-2025 | |
| Spinal Simplicity, LLC | $1,080.37 | 2019 | |
| Seaspine Orthopedics Corporation | $874.12 | 2021-2022 | |
| Medtronic, INC. | $843.64 | 2021-2025 | Kyphon Express II Kyphopak Tray, Mazor X System, Infinity Occipitocervical Upper Thoracic System |
| Integra Lifesciences Corporation | $313.03 | 2019-2021 | |
| Stryker Corporation | $267.41 | 2019-2025 | Universal Neuro 3, Duramatrix, Hydroset |
| Intrinsic Therapeutics | $175.00 | 2025 | Barricaid Acd (Annular Closure Device) |
| Monteris Medical Corporation | $138.56 | 2019-2025 | Neuroblate |
| Medtronic USA, INC. | $135.79 | 2019-2020 | |
| Boston Scientific Corporation | $128.73 | 2019-2025 | General - Pain Management |
| Aesculap, INC. | $49.15 | 2025 | Gav, Aesculap |
| Nevro Corp. | $48.85 | 2019-2024 | Senza |
| Kls-Martin L.P. | $41.41 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nico Corporation | $35.00 | 2024 | |
| Bioventus LLC | $31.80 | 2024 | Bonescalpel & Sonicone (O.R.) |
| Livanova USA, INC. | $27.44 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Nexxt Spine LLC | $27.35 | 2024 | Matrixx Lateral Expandable |
| Saluda Medical Americas, INC. | $11.93 | 2024 | Evoke |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,671,185.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.